Everything below concerns research compound. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-02. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
=== Initial adoption === Due to the influence tire pressure has on vehicle safety and efficiency, tire-pressure monitoring (TPM) was adopted by the European market as an optional feature for luxury passenger vehicles in the 1980s. The first passenger vehicle to adopt TPM was the Porsche 959 in 1986, using a hollow spoke wheel system developed by PSK. In 1996 Renault used the Michelin PAX system for the Scenic and in 1999 PSA Peugeot Citroën decided to adopt TPM as a standard feature on the Peugeot 607. The following year (2000), Renault launched the Laguna II, the first high volume mid-size passenger vehicle in the world to be equipped with TPM as a standard feature. In the United States, TPM was introduced by General Motors for the 1991 model year for the Corvette in conjunction with Goodyear run-flat tires. The system uses sensors in the wheels and a driver display which can show tire pressure at any wheel, plus warnings for both high and low pressure. It has been standard on Corvettes ever since.
=== Animals === In cats (and some dogs and ferrets) vaccine-associated sarcoma (VAS) or feline injection-site sarcoma (FISS) occurs at a rate of 1–10 per 10,000 injections. In 1993, a causal relationship between VAS and administration of aluminium-adjuvated rabies and FeLV vaccines was established through epidemiologic methods, and in 1996 the Vaccine-Associated Feline Sarcoma Task Force was formed to address the problem. FISS is characterized by an unintentionally prolonged inflammation at the injection site and an imappropriate respose by the other cells to the inflammation. However, evidence conflicts on whether types of vaccines, manufacturers or factors have been associated with sarcomas. It is unknown why humans do not have this reaction.
A type of study in which the patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given. The opposite of a blinded study is an open label study. (NCI)
Sources: en.wikipedia.org
The Committee on International Affairs of the State Duma (Russian: Комитет Государственной Думы по международным делам) is a committee of the State Duma, the lower house of Russia's Federal Assembly. The Committee carries out activities in the field of implementation of Russia's foreign policy, international contacts of the State Duma, work in interparliamentary structures, and relations with parliaments of other states. The Committee checks the international treaties subject to ratification and gives its conclusion, after which the draft treaties are put to the vote of the State Duma. Also, the Committee considers candidates proposed by the Russian President for the posts of ambassadors to foreign countries and international organizations and makes its recommendations regarding their appointment to the proposed positions.
The decay of 40K in Earth's mantle ranks third, after 232Th and 238U, in the list of sources of radiogenic heat. Less is known about the amount of radiogenic sources in Earth's outer and inner core, which lie below the mantle. It has been proposed, though, that significant core radioactivity (1–2 TW) may be caused by high levels of U, Th and K. Potassium-40 is the largest source of natural radioactivity in animals including humans. A 70 kg human body contains about 140 g (or 126 g) of potassium, hence about 140g × 0.0117% * (39.96/39.10) ≈ 16.7 mg of 40K; whose decay produces about 3,850 to 4,300 disintegrations per second (becquerel) continuously throughout the life of an adult person (and proportionally less in children). The normal potassium-40 concentration in the human body is equivalent to 55 Bq per kilogram, corresponding to an effective dose of 0.2 millisievert per year throughout the body. This is the largest source of internal radiation, followed by 0.12 mSv per year from the nuclides in the uranium and thorium decay series, and just 12 microsieverts per year from carbon-14.
=== Sentencing === In 1998, there were wide racial disparities in arrests, prosecutions, sentencing, and deaths. Black people, despite being only 13% of regular drug users, made up for 35% of drug arrests, 55% of convictions, and 74% of people sent to prison for drug possession crimes. Nationwide African-Americans were sent to state prisons for drug offenses 13 times more often than white men. Crime statistics show that in 1999 in the United States, blacks were far more likely to be targeted by law enforcement for drug crimes, and they received much stiffer penalties and sentences than whites. A 2000 study found that the disproportionality of black drug offenders in Pennsylvania prisons was unexplained by higher arrest rates, which suggested the possibility of operative discrimination in sentencing. A 2008 paper stated that drug use rates by blacks (7.4%) were comparable to those by whites (7.2%), and since there are far more whites than blacks, 72% of illegal drug users in America are white, and only 15% are black. According to Michelle Alexander, the author of The New Jim Crow and a professor of law at Stanford Law School, drug trading is done at similar rates all over the US, but most people arrested for it are colored. Together, blacks and Hispanics were 58% of all prisoners in 2008 but only one quarter of the US population. Most prisoners are arrested for drug related crime, and in at least 15 states, three quarters of them are black or Latino.
Sources: en.wikipedia.org
=== Assessment and physical examination === Catatonia is often overlooked and under-diagnosed. Most patients present with an underlying psychiatric disorder, which can obscure recognition of catatonia. For example, psychotic symptoms may dominate the clinical picture, while classic catatonic features (such as mutism or posturing) are absent. Motor abnormalities can also be misleading; in mania, increased motor activity is typically goal-directed, whereas in excited catatonia, activity is non–goal-directed and repetitive. Careful observation of motor behavior is therefore crucial for diagnosis. Catatonia remains a clinical diagnosis with no specific laboratory test to diagnose it. However, supportive investigations may help identify underlying causes:
At this point, a fully working vaccine has not been created, and it is therefore decided that the best thing for the Syndicate to do is to comply with the original deal and turn over the hybrid to the Colonists in the hope that they are spared the resulting takeover. Before this can be done, however, the Rebels kill all but a few members of the Syndicate in addition to Cassandra, the only living successful alien-human hybrid, before the Syndicate is able to send a signal to the Colonists. Without a successful hybrid, the timetable for the Colonist invasion will not be advanced and the date set for colonization remains December 22, 2012.
=== Acidity === Thiols are easily deprotonated. Relative to the alcohols, thiols are more acidic. The conjugate base of a thiol is called a thiolate. Butanethiol has a pKa of 10.5 vs 15 for butanol. Thiophenol has a pKa of 6, versus 10 for phenol. A highly acidic thiol is pentafluorothiophenol (C6F5SH) with a pKa of 2.68. Thus, thiolates can be obtained from thiols by treatment with alkali metal hydroxides.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.